JP2003527069A - セファロスポリンのｉｎｖｉｖｏ製造の改善 - Google Patents
セファロスポリンのｉｎｖｉｖｏ製造の改善Info
- Publication number
- JP2003527069A JP2003527069A JP2000549710A JP2000549710A JP2003527069A JP 2003527069 A JP2003527069 A JP 2003527069A JP 2000549710 A JP2000549710 A JP 2000549710A JP 2000549710 A JP2000549710 A JP 2000549710A JP 2003527069 A JP2003527069 A JP 2003527069A
- Authority
- JP
- Japan
- Prior art keywords
- expandase
- dna fragment
- host cell
- host
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 26
- 150000001780 cephalosporins Chemical class 0.000 title abstract description 32
- 229930186147 Cephalosporin Natural products 0.000 title abstract description 29
- 229940124587 cephalosporin Drugs 0.000 title abstract description 29
- 238000001727 in vivo Methods 0.000 title abstract description 8
- 101710104123 Deacetoxycephalosporin C synthase Proteins 0.000 claims abstract description 106
- 210000004027 cell Anatomy 0.000 claims abstract description 55
- 238000000034 method Methods 0.000 claims abstract description 42
- 210000002500 microbody Anatomy 0.000 claims abstract description 34
- 210000000172 cytosol Anatomy 0.000 claims abstract description 30
- 239000012634 fragment Substances 0.000 claims description 43
- 241000228150 Penicillium chrysogenum Species 0.000 claims description 29
- -1 beta-lactam compound Chemical class 0.000 claims description 29
- 238000012986 modification Methods 0.000 claims description 19
- 230000004048 modification Effects 0.000 claims description 19
- 241000233866 Fungi Species 0.000 claims description 14
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 210000004899 c-terminal region Anatomy 0.000 claims description 11
- 230000009466 transformation Effects 0.000 claims description 11
- 241000187747 Streptomyces Species 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- 244000005700 microbiome Species 0.000 claims description 7
- 241000228431 Acremonium chrysogenum Species 0.000 claims description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 238000006049 ring expansion reaction Methods 0.000 claims description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 241000351920 Aspergillus nidulans Species 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical group OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Chemical group SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Chemical group OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 235000004400 serine Nutrition 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 125000003460 beta-lactamyl group Chemical group 0.000 claims 1
- 150000001782 cephems Chemical class 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 230000000644 propagated effect Effects 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 abstract description 47
- 108090000790 Enzymes Proteins 0.000 abstract description 47
- 210000002824 peroxisome Anatomy 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 5
- 238000013519 translation Methods 0.000 abstract description 3
- 238000013518 transcription Methods 0.000 abstract description 2
- 230000035897 transcription Effects 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 25
- 229930182555 Penicillin Natural products 0.000 description 21
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 18
- 229940049954 penicillin Drugs 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 101150091913 cefE gene Proteins 0.000 description 9
- 230000008685 targeting Effects 0.000 description 9
- 238000009826 distribution Methods 0.000 description 8
- 238000000855 fermentation Methods 0.000 description 8
- 230000004151 fermentation Effects 0.000 description 8
- NVIAYEIXYQCDAN-MHTLYPKNSA-N (6r,7s)-7-azaniumyl-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound S1CC(C)=C(C([O-])=O)N2C(=O)[C@H]([NH3+])[C@@H]12 NVIAYEIXYQCDAN-MHTLYPKNSA-N 0.000 description 7
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 150000002960 penicillins Chemical class 0.000 description 7
- 230000008569 process Effects 0.000 description 6
- 241000187390 Amycolatopsis lactamdurans Species 0.000 description 5
- MIFYHUACUWQUKT-UHFFFAOYSA-N Isopenicillin N Natural products OC(=O)C1C(C)(C)SC2C(NC(=O)CCCC(N)C(O)=O)C(=O)N21 MIFYHUACUWQUKT-UHFFFAOYSA-N 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000004807 localization Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 150000003952 β-lactams Chemical class 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 229950008644 adicillin Drugs 0.000 description 4
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- MIFYHUACUWQUKT-GPUHXXMPSA-N penicillin N Chemical compound OC(=O)[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)CCC[C@@H](N)C(O)=O)C(=O)N21 MIFYHUACUWQUKT-GPUHXXMPSA-N 0.000 description 4
- 210000001938 protoplast Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000057234 Acyl transferases Human genes 0.000 description 3
- 108700016155 Acyl transferases Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 241000589516 Pseudomonas Species 0.000 description 3
- 239000001361 adipic acid Substances 0.000 description 3
- 235000011037 adipic acid Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 108010005802 desacetoxycephalosporin C synthetase Proteins 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- ODJQKYXPKWQWNK-UHFFFAOYSA-N 3,3'-Thiobispropanoic acid Chemical compound OC(=O)CCSCCC(O)=O ODJQKYXPKWQWNK-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000228245 Aspergillus niger Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HOKIDJSKDBPKTQ-GLXFQSAKSA-N Cephalosporin C Natural products S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CCC[C@@H](N)C(O)=O)[C@@H]12 HOKIDJSKDBPKTQ-GLXFQSAKSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108700005088 Fungal Genes Proteins 0.000 description 2
- 101710107944 Isopenicillin N synthase Proteins 0.000 description 2
- 239000004201 L-cysteine Substances 0.000 description 2
- 235000013878 L-cysteine Nutrition 0.000 description 2
- 241000228143 Penicillium Species 0.000 description 2
- 241000228417 Sarocladium strictum Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000187433 Streptomyces clavuligerus Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- HOKIDJSKDBPKTQ-GLXFQSAKSA-M cephalosporin C(1-) Chemical compound S1CC(COC(=O)C)=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CCC[C@@H]([NH3+])C([O-])=O)[C@@H]12 HOKIDJSKDBPKTQ-GLXFQSAKSA-M 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 125000003651 hexanedioyl group Chemical group C(CCCCC(=O)*)(=O)* 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000013587 production medium Substances 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000011191 terminal modification Methods 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 239000002132 β-lactam antibiotic Substances 0.000 description 2
- 229940124586 β-lactam antibiotics Drugs 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- NWWJFMCCTZLKNT-UHFFFAOYSA-N 3,4-dihydro-2h-thiazine Chemical group C1CC=CSN1 NWWJFMCCTZLKNT-UHFFFAOYSA-N 0.000 description 1
- RKWPEWMDPJMQAB-UHFFFAOYSA-N 3-methyl-4-oxo-4-sulfanylbutanoic acid Chemical compound SC(=O)C(C)CC(O)=O RKWPEWMDPJMQAB-UHFFFAOYSA-N 0.000 description 1
- 241001019659 Acremonium <Plectosphaerellaceae> Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 102100033779 Collagen alpha-4(IV) chain Human genes 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102100036738 Guanine nucleotide-binding protein subunit alpha-11 Human genes 0.000 description 1
- 101000710870 Homo sapiens Collagen alpha-4(IV) chain Proteins 0.000 description 1
- 101100283445 Homo sapiens GNA11 gene Proteins 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- PKEXHDRGMPOQQN-RZVRUWJTSA-N N[C@H](C(=O)O)CCCC(=O)O.N[C@@H](CCCC(=O)O)C(=O)O Chemical compound N[C@H](C(=O)O)CCCC(=O)O.N[C@@H](CCCC(=O)O)C(=O)O PKEXHDRGMPOQQN-RZVRUWJTSA-N 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108010073038 Penicillin Amidase Proteins 0.000 description 1
- 229930195708 Penicillin V Natural products 0.000 description 1
- 241000284696 Penicillium rubens Wisconsin 54-1255 Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010085186 Peroxisomal Targeting Signals Proteins 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000589746 Pseudomonas sp. SE83 Species 0.000 description 1
- 101001062854 Rattus norvegicus Fatty acid-binding protein 5 Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- GZSZPKSBVAOGIE-CIUDSAMLSA-N Ser-Lys-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O GZSZPKSBVAOGIE-CIUDSAMLSA-N 0.000 description 1
- 241000187180 Streptomyces sp. Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- UCKZMPLVLCKKMO-LHLIQPBNSA-N cephamycin Chemical compound S1CC(C)=C(C(O)=O)N2C(=O)[C@@H](C)[C@]21OC UCKZMPLVLCKKMO-LHLIQPBNSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012993 chemical processing Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- NNQIJOYQWYKBOW-JWKOBGCHSA-N deacetoxycephalosporin C Chemical compound S1CC(C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CCC[C@@H](N)C(O)=O)[C@@H]12 NNQIJOYQWYKBOW-JWKOBGCHSA-N 0.000 description 1
- 230000020176 deacylation Effects 0.000 description 1
- 238000005947 deacylation reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- JSYGRUBHOCKMGQ-UHFFFAOYSA-N dichloramine Chemical group ClNCl JSYGRUBHOCKMGQ-UHFFFAOYSA-N 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 101150055760 glcA gene Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- YVSCCMNRWFOKDU-UHFFFAOYSA-N hexanedioic acid Chemical compound OC(=O)CCCCC(O)=O.OC(=O)CCCCC(O)=O YVSCCMNRWFOKDU-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- MIFYHUACUWQUKT-GTQWGBSQSA-N isopenicillin N Chemical compound OC(=O)[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)CCC[C@H](N)C(O)=O)C(=O)N21 MIFYHUACUWQUKT-GTQWGBSQSA-N 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 101150074325 pcbC gene Proteins 0.000 description 1
- 229940056367 penicillin v Drugs 0.000 description 1
- 230000000858 peroxisomal effect Effects 0.000 description 1
- 125000000864 peroxy group Chemical group O(O*)* 0.000 description 1
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P35/00—Preparation of compounds having a 5-thia-1-azabicyclo [4.2.0] octane ring system, e.g. cephalosporin
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Cephalosporin Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98201655.2 | 1998-05-19 | ||
| EP98201655 | 1998-05-19 | ||
| PCT/EP1999/003455 WO1999060102A2 (en) | 1998-05-19 | 1999-05-19 | Improved in vivo production of cephalosporins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003527069A true JP2003527069A (ja) | 2003-09-16 |
| JP2003527069A5 JP2003527069A5 (enExample) | 2006-07-06 |
Family
ID=8233737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000549710A Withdrawn JP2003527069A (ja) | 1998-05-19 | 1999-05-19 | セファロスポリンのｉｎｖｉｖｏ製造の改善 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6995003B1 (enExample) |
| EP (2) | EP1078069B1 (enExample) |
| JP (1) | JP2003527069A (enExample) |
| KR (1) | KR100648480B1 (enExample) |
| CN (2) | CN101353660A (enExample) |
| AT (1) | ATE386123T1 (enExample) |
| AU (1) | AU4144999A (enExample) |
| BR (1) | BR9910532A (enExample) |
| DE (1) | DE69938129D1 (enExample) |
| ES (1) | ES2302379T3 (enExample) |
| ID (1) | ID27054A (enExample) |
| MX (1) | MXPA00011223A (enExample) |
| PL (1) | PL344863A1 (enExample) |
| RU (1) | RU2230790C2 (enExample) |
| WO (1) | WO1999060102A2 (enExample) |
| ZA (1) | ZA200006308B (enExample) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0011185D0 (en) * | 2000-05-09 | 2000-06-28 | Synpac Pharmaceuticals Limited | Protein |
| CN1796537B (zh) * | 2004-12-23 | 2010-09-08 | 华北制药集团有限责任公司 | 一种新的产黄青霉菌株以及利用此菌株发酵制备青霉素 |
| US20060217971A1 (en) * | 2005-03-28 | 2006-09-28 | Tellabs Operations, Inc. | Method and apparatus for modifying an encoded signal |
| EP2220234B1 (en) | 2007-11-20 | 2012-06-27 | DSM IP Assets B.V. | Dicarboxylic acid production in a recombinant yeast |
| WO2009065777A1 (en) | 2007-11-20 | 2009-05-28 | Dsm Ip Assets B.V. | Dicarboxylic acid production in a filamentous fungus |
| CN104818224A (zh) | 2007-11-20 | 2015-08-05 | 帝斯曼知识产权资产管理有限公司 | 在真核细胞中生产琥珀酸 |
| EP2116136A1 (en) | 2008-05-08 | 2009-11-11 | Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO | Novel phytases |
| EP2408907B8 (en) | 2009-03-17 | 2018-04-18 | Dutch DNA Biotech B.V. | Use of cellulose and ligno-cellulose active proteins |
| WO2010118932A1 (en) | 2009-04-15 | 2010-10-21 | Dsm Ip Assets B.V. | Dicarboxylic acid production process |
| UA108853C2 (uk) | 2009-07-10 | 2015-06-25 | Спосіб ферментації галактози | |
| EA201201449A1 (ru) | 2010-04-21 | 2013-03-29 | ДСМ АйПи АССЕТС Б.В. | Способ получения клеток, способных преобразовывать арабинозу |
| EP2388331A1 (en) | 2010-05-21 | 2011-11-23 | Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO | Constitutive promoter |
| MY160995A (en) | 2010-10-13 | 2017-03-28 | Dsm Ip Assets Bv | Polypeptides with permease activity |
| EA201301193A1 (ru) | 2011-04-22 | 2014-02-28 | ДСМ АйПи АССЕТС Б.В. | Дрожжевые клетки, способные к превращению сахаров, содержащих арабинозу и ксилозу |
| AR087423A1 (es) | 2011-08-04 | 2014-03-19 | Dsm Ip Assets Bv | Celula capaz de fermentar azucares pentosas |
| EP2554668A1 (en) | 2011-08-04 | 2013-02-06 | DSM IP Assets B.V. | A pentose sugar fermenting cell |
| EA201400836A8 (ru) | 2012-01-23 | 2016-03-31 | ДСМ АйПи АССЕТС Б.В. | Получение дитерпена |
| CN104718280A (zh) | 2012-10-16 | 2015-06-17 | 帝斯曼知识产权资产管理有限公司 | 具有改善的戊糖转化的细胞 |
| EP2772545A1 (en) | 2013-03-01 | 2014-09-03 | Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO | Starch active proteins |
| EP2981610A1 (en) | 2013-04-05 | 2016-02-10 | Université du Luxembourg | Biotechnological production of itaconic acid |
| EP2992105A1 (en) | 2013-05-02 | 2016-03-09 | Dutch DNA Biotech B.V. | Novel organic acid pathway |
| CA2913876A1 (en) | 2013-05-31 | 2014-12-04 | Dsm Ip Assets B.V. | Microorganisms for diterpene production |
| AU2014292150B2 (en) | 2013-07-15 | 2019-04-04 | Dsm Ip Assets B.V. | Diterpene production |
| EP3536697A1 (en) | 2013-07-31 | 2019-09-11 | DSM IP Assets B.V. | Recovery of steviol glycosides |
| EP3259361A1 (en) | 2015-02-16 | 2017-12-27 | DSM IP Assets B.V. | Process for producing itaconic acid under anaerobic conditions |
| CA2979931A1 (en) | 2015-03-16 | 2016-09-22 | Dsm Ip Assets B.V. | Udp-glycosyltransferases |
| CA2979957A1 (en) | 2015-03-23 | 2016-09-29 | Dsm Ip Assets B.V. | Udp-glycosyltransferases from solanum lycopersicum |
| EP3718417B1 (en) | 2015-04-03 | 2025-09-03 | DSM IP Assets B.V. | Steviol glycosides |
| CN107532135A (zh) | 2015-04-21 | 2018-01-02 | 帝斯曼知识产权资产管理有限公司 | 萜类化合物的微生物生产 |
| MY186983A (en) | 2015-05-22 | 2021-08-26 | Dsm Ip Assets Bv | Acetate consuming yeast cell |
| EP3320104B1 (en) | 2015-07-10 | 2021-11-10 | DSM IP Assets B.V. | Method for preparing a steviol glycoside composition |
| CA2993744A1 (en) | 2015-08-13 | 2017-02-16 | Dsm Ip Assets B.V. | Steviol glycoside transport |
| WO2017050652A1 (en) | 2015-09-25 | 2017-03-30 | Dsm Ip Assets B.V. | Asparaginase |
| CA2999638A1 (en) | 2015-10-05 | 2017-04-13 | Dsm Ip Assets B.V. | Kaurenoic acid hydroxylases |
| EP3359655B1 (en) | 2015-10-06 | 2019-11-20 | DSM IP Assets B.V. | Eukaryotic cell with increased production of fermentation product |
| WO2017115323A2 (en) | 2015-12-30 | 2017-07-06 | Dsm Ip Assets B.V. | Partial enzymatic hydrolysis of triacylglycerols |
| WO2017115322A2 (en) | 2015-12-30 | 2017-07-06 | Dsm Ip Assets B.V. | Partial enzymatic hydrolysis of triacylglycerols |
| WO2017167847A1 (en) | 2016-03-31 | 2017-10-05 | Dsm Ip Assets B.V. | Production of milk with low lactose content |
| EP3435772A1 (en) | 2016-03-31 | 2019-02-06 | DSM IP Assets B.V. | Enzyme composition and preparation of a dairy product with improved properties |
| WO2017167848A1 (en) | 2016-03-31 | 2017-10-05 | Dsm Ip Assets B.V. | Enzyme composition and preparation of a dairy product with improved properties |
| CN109312296B (zh) | 2016-06-14 | 2023-05-05 | 帝斯曼知识产权资产管理有限公司 | 重组酵母细胞 |
| EP3919615A1 (en) | 2016-07-13 | 2021-12-08 | DSM IP Assets B.V. | Malate dehyrogenases |
| EP3497109A1 (en) | 2016-08-09 | 2019-06-19 | DSM IP Assets B.V. | Crystallization of steviol glycosides |
| EP3497110A1 (en) | 2016-08-09 | 2019-06-19 | DSM IP Assets B.V. | Crystallization of steviol glycosides |
| CN110036114B (zh) | 2016-08-26 | 2023-09-29 | 勒萨弗尔公司 | 提高的衣康酸生产 |
| WO2018073107A1 (en) | 2016-10-19 | 2018-04-26 | Dsm Ip Assets B.V. | Eukaryotic cell comprising xylose isomerase |
| WO2018078014A1 (en) | 2016-10-27 | 2018-05-03 | Dsm Ip Assets B.V. | Geranylgeranyl pyrophosphate synthases |
| JP2020500520A (ja) | 2016-12-08 | 2020-01-16 | ディーエスエム アイピー アセッツ ビー．ブイ．Ｄｓｍ Ｉｐ Ａｓｓｅｔｓ Ｂ．Ｖ． | カウレン酸ヒドロキシラーゼ |
| WO2018114912A1 (en) | 2016-12-21 | 2018-06-28 | Dsm Ip Assets B.V. | Lipolytic enzyme variants |
| EP3559222A1 (en) | 2016-12-21 | 2019-10-30 | DSM IP Assets B.V. | Lipolytic enzyme variants |
| US10889807B2 (en) | 2016-12-21 | 2021-01-12 | Dsm Ip Assets B.V. | Lipolytic enzyme variants |
| WO2018114938A1 (en) | 2016-12-21 | 2018-06-28 | Dsm Ip Assets B.V. | Lipolytic enzyme variants |
| WO2018114995A1 (en) | 2016-12-22 | 2018-06-28 | Dsm Ip Assets B.V. | Fermentation process for producing steviol glycosides |
| CA3064143A1 (en) | 2017-06-13 | 2018-12-20 | Dsm Ip Assets B.V. | Recombinant yeast cell |
| EP4155400A1 (en) | 2017-06-27 | 2023-03-29 | DSM IP Assets B.V. | Udp-glycosyltransferases |
| CN111133111A (zh) | 2017-09-26 | 2020-05-08 | 帝斯曼知识产权资产管理有限公司 | 消耗乙酸的菌株 |
| EP3533878A1 (en) | 2018-02-28 | 2019-09-04 | Dutch DNA Biotech B.V. | Process for producing citramalic acid employing aspergillus |
| MX2020014191A (es) | 2018-06-19 | 2021-03-09 | Dsm Ip Assets Bv | Variantes de enzimas lipoliticas. |
| EP4232568A1 (en) | 2020-10-22 | 2023-08-30 | DSM IP Assets B.V. | Microorganisms for diterpene production |
| WO2022269549A2 (en) | 2021-06-24 | 2022-12-29 | Fonterra Co-Operative Group Limited | Recombinant proteins |
| US20250333768A1 (en) | 2021-07-12 | 2025-10-30 | Danisco Us Inc. | Recombinant yeast cell |
| WO2023285280A1 (en) | 2021-07-12 | 2023-01-19 | Dsm Ip Assets B.V. | Recombinant yeast cell |
| MX2024000606A (es) | 2021-07-12 | 2024-01-30 | Danisco Us Inc | Celula de levadura recombinante. |
| EP4370692A1 (en) | 2021-07-12 | 2024-05-22 | Danisco Us Inc | Recombinant yeast cell |
| MX2024000513A (es) | 2021-07-12 | 2024-03-27 | Danisco Us Inc | Celula de levadura recombinante. |
| CN117916381A (zh) | 2021-07-12 | 2024-04-19 | 丹尼斯科美国公司 | 重组酵母细胞 |
| EP4426824A1 (en) | 2021-11-04 | 2024-09-11 | Danisco US Inc. | Recombinant yeast cell |
| US20240425888A1 (en) | 2021-11-04 | 2024-12-26 | Danisco Us Inc. | Process for the production of ethanol and recombinant yeast cell |
| US20240409965A1 (en) | 2021-11-04 | 2024-12-12 | Danisco Us Inc. | Variant polypeptide and recombinant yeast cell |
| EP4430174A1 (en) | 2021-11-09 | 2024-09-18 | Amgen Inc. | Production of therapeutic proteins |
| JP2025520009A (ja) | 2022-05-16 | 2025-07-01 | ディーエスエム アイピー アセッツ ビー．ブイ． | 脂肪分解酵素変異体 |
| CN121127603A (zh) | 2023-04-20 | 2025-12-12 | 帝斯曼知识产权资产管理有限公司 | 用于产生罗汉果苷的菌株和方法 |
| WO2025012325A1 (en) | 2023-07-11 | 2025-01-16 | Dsm Ip Assets B.V. | Protein arginine deiminase |
| WO2025144785A2 (en) | 2023-12-28 | 2025-07-03 | Dsm Ip Assets B.V. | Cells and methods for the production of glycosylated compounds |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4003894A (en) | 1971-08-17 | 1977-01-18 | Gist-Brocades N.V. | Preparation of 7-substituted amino-desacetoxycephalosporanic acid compounds |
| PT83746B (pt) | 1985-11-15 | 1988-08-17 | Gist Brocades Nv | Processo para a preparacao de novos biocatalisadores imobilizados e para a producao de etanol por fermentacao |
| US5070020A (en) * | 1988-05-09 | 1991-12-03 | Eli Lilly And Company | Recombinant dna expression vectors and dna compounds that encode deacetoxycephalosporin c synthetase |
| US5082772A (en) | 1988-10-24 | 1992-01-21 | Eli Lilly And Company | Process for preparing deacetylcephalosporin c |
| PT97116B (pt) * | 1990-03-23 | 1998-10-30 | Gist Brocades Nv | Processo para modular a producao de metabolitos secundarios nomeadamente derivados de beta-lactama |
| US5318896A (en) | 1991-09-11 | 1994-06-07 | Merck & Co., Inc. | Recombinant expandase bioprocess for preparing 7-aminodesacetoxy cephalosporanic acid (7-ADCA) |
| UA47385C2 (uk) * | 1991-10-15 | 2002-07-15 | Гіст-Брокейдс Б.В. | Спосіб одержання 7-амінодеацетилцефалоспоранової кислоти, спосіб одержання 7-аміноцефалоспоранової кислоти, вектор експресії рекомбінантної днк (варіанти), клітина-хазяїн penicillium chrysogenum (варіанти), спосіб культивування рекомбінантної клітини-хазяїна penicillium chrysogenum (варіанти) |
| EP1321523A3 (en) | 1993-07-23 | 2004-03-03 | DSM IP Assets B.V. | Selection marker gene free recombinant strains; a method for obtaining them and the use of these strains |
| PL180565B1 (pl) * | 1993-07-30 | 2001-02-28 | Gist Brocades Bv | Sposób wytwarzaniai wydzielania kwasu 7-aminodezacetoksycefalosporanowego (7-ADCA) PL PL |
| WO1995004148A1 (en) | 1993-07-30 | 1995-02-09 | Gist-Brocades B.V. | Process for the efficient production of 7-adca via 2-(carboxyethylthio)acetyl-7-adca and 3-(carboxymethylthio)propionyl-7-adca |
| WO1997020053A2 (en) | 1995-11-27 | 1997-06-05 | Gist-Brocades B.V. | Improved process for the production of semi-synthetic cephalosporins via expandase activity on penicillin g |
| AU4114697A (en) | 1996-07-16 | 1998-02-09 | Gist-Brocades B.V. | Improved process for the production of adipoyl cephalosporins |
-
1999
- 1999-05-19 WO PCT/EP1999/003455 patent/WO1999060102A2/en not_active Ceased
- 1999-05-19 AU AU41449/99A patent/AU4144999A/en not_active Abandoned
- 1999-05-19 JP JP2000549710A patent/JP2003527069A/ja not_active Withdrawn
- 1999-05-19 EP EP99925015A patent/EP1078069B1/en not_active Expired - Lifetime
- 1999-05-19 PL PL99344863A patent/PL344863A1/xx not_active Application Discontinuation
- 1999-05-19 AT AT99925015T patent/ATE386123T1/de not_active IP Right Cessation
- 1999-05-19 CN CNA2008100875582A patent/CN101353660A/zh active Pending
- 1999-05-19 RU RU2000131687/13A patent/RU2230790C2/ru not_active IP Right Cessation
- 1999-05-19 ID IDW20002338A patent/ID27054A/id unknown
- 1999-05-19 CN CNB998063142A patent/CN100390285C/zh not_active Expired - Lifetime
- 1999-05-19 US US09/700,080 patent/US6995003B1/en not_active Expired - Fee Related
- 1999-05-19 KR KR1020007012957A patent/KR100648480B1/ko not_active Expired - Fee Related
- 1999-05-19 EP EP08101461A patent/EP1953230A1/en not_active Withdrawn
- 1999-05-19 DE DE69938129T patent/DE69938129D1/de not_active Expired - Lifetime
- 1999-05-19 ES ES99925015T patent/ES2302379T3/es not_active Expired - Lifetime
- 1999-05-19 BR BR9910532-2A patent/BR9910532A/pt not_active Application Discontinuation
- 1999-05-19 MX MXPA00011223A patent/MXPA00011223A/es unknown
-
2000
- 2000-11-03 ZA ZA200006308A patent/ZA200006308B/en unknown
-
2006
- 2006-02-07 US US11/349,381 patent/US20060127972A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN101353660A (zh) | 2009-01-28 |
| US20060127972A1 (en) | 2006-06-15 |
| ES2302379T3 (es) | 2008-07-01 |
| RU2230790C2 (ru) | 2004-06-20 |
| WO1999060102A3 (en) | 2000-02-03 |
| AU4144999A (en) | 1999-12-06 |
| EP1078069B1 (en) | 2008-02-13 |
| CN1301303A (zh) | 2001-06-27 |
| EP1078069A2 (en) | 2001-02-28 |
| ATE386123T1 (de) | 2008-03-15 |
| ZA200006308B (en) | 2001-05-23 |
| KR100648480B1 (ko) | 2006-11-24 |
| DE69938129D1 (de) | 2008-03-27 |
| EP1953230A1 (en) | 2008-08-06 |
| PL344863A1 (en) | 2001-11-19 |
| US6995003B1 (en) | 2006-02-07 |
| ID27054A (id) | 2001-02-22 |
| BR9910532A (pt) | 2001-10-16 |
| WO1999060102A2 (en) | 1999-11-25 |
| MXPA00011223A (es) | 2002-04-17 |
| CN100390285C (zh) | 2008-05-28 |
| KR20010025039A (ko) | 2001-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003527069A (ja) | セファロスポリンのｉｎｖｉｖｏ製造の改善 | |
| KR100336174B1 (ko) | 2-(카르복시에틸티오)아세틸-7-adca및3-(카르복시메틸티오)프로피오닐-7-adca를경유하여7-adca를제조하는효율적인방법 | |
| JP3574453B2 (ja) | ３‐（カルボキシエチルチオ）プロピオニル‐７‐ａｄｃａを経由した７‐ａｄｃａの効果的な製造法 | |
| EP1141372A2 (en) | Improved in vivo production of cephalosporins | |
| NO315802B1 (no) | Biologisk fremgangsmåte for fremstilling av 7-ACA og 7-ADAC | |
| HU205387B (en) | Process for producing deacetoxy-cefalosporin-c-synthetase and protein having deacetyl-cefalosporin-c-synthetase activity, host cells capable of expressing protein, as well as cefalosporin | |
| WO2006061425A2 (en) | Production of beta-lactam antibiotics by genetically modified non-naturally producing microorganisms | |
| JP2006528970A (ja) | セフェム化合物 | |
| WO2001085951A1 (en) | A modified expandase and uses thereof | |
| JP3764166B2 (ja) | 二次代謝産物を産生するための方法 | |
| JP2000512512A (ja) | 脱アシル化セファロスポリンの発酵による製造方法 | |
| WO1998002551A2 (en) | Process for the production of adipoyl cephalosporins | |
| US5882879A (en) | Method for influencing β-lactam antibiotic production and for isolation of large quantities of ACV synthetase | |
| EP0444758A1 (en) | Method for modification of ACV synthetase and use of the modified enzyme for production of beta-lactam antibiotics | |
| EP0716698B1 (en) | Process for the efficient production of 7-ADCA via 2-(carboxyethylthio)acetyl-7-ADCA and 3-(carboxymethylthio)propionyl-7-ADCA | |
| HK1036480A (en) | Improved in vivo production of cephalosporins | |
| RU2139349C1 (ru) | Способ эффективного производства 7-адцк через 2-(карбоксиэтилтио) ацетил-7-адцк и 3-(карбоксиметилтио)пропионил-7-адцк | |
| RU2139350C1 (ru) | Способ эффективного производства 7-адцк через 3-(карбоксиэтилтио)пропионил-7-адцк | |
| WO1997038107A1 (en) | An enzyme with high adipoyl-coenzyme a synthetase activity and uses thereof | |
| JPH09503907A (ja) | ２−（カルボキシエチルチオ）アセチル−７−ａｄｃａ及び３−（カルボキシメチルチオ）プロピオニル−７−ａｄｃａを経由した７−ａｄｃａの効果的な製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060518 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060518 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20061006 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20061011 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20070122 |